News
-
24-Feb-2012
Novartis works for patients with rare diseasesFrom pioneering Novartis medicines used by patients worldwide to treat rare forms of cancer to potential medical breakthroughs now undergoing clinical testing, our commitment to rare diseases has never been stronger. Underscoring that commitment, Novartis headquarters in Basel, Switzerland, will host the RE(ACT) Congress, the first international congress on research of rare and orphan diseases, from February 29 to March 2.
-
22-Feb-2012
Delivery of child-friendly antimalarial hits the 100 million markIn 2009, Novartis and MMV launched the first child friendly artemisinin-combination therapy (ACT), meeting the calls from UNICEF and the WHO for age-appropriate medicines. Three years after launch, deliveries of this child-friendly antimalarial hit the 100 million mark.
Learn more how Novartis is adressing the unmet needs of children
-
30-Jan-2012
Novartis continues fight to help end leprosyNovartis announced today that it will extend its collaboration with the World Health Organization and others to end leprosy.
